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INTRODUCTION
The genome of HIV-1 encodes Vif as one of ac-
cessory viral proteins that are unique to primate
immunodeficiency viruses. HIV -1 Vif efficiently
neutralizes the strong anti - retroviral effects of
APOBEC3G/APOBEC3F in natural target cells by
targeting them to proteasomal degradation (1).
Through this activity of Vif, HIV-1 can grow in T
lymphocytes and macrophages, the two major tar-
gets cells of the virus. Extensive studies by us and
others have revealed that HIV-1 Vif consists of two
major functional domains with various motifs (2-4).
HIV-1 Vif binds to APOBEC3G/APOBEC3F by its
N - terminal region (2 - 10), and degrades them
through interaction with its C - terminal region
(2, 11-14). While Vif mediates proteasomal degra-
dation of both APOBEC3 proteins, it binds to them
differently via several distinct motifs (2-10). In some
CD4+ cells such as H9, primary T lymphocytes, and
macrophages that are non-permissive for HIV-1
without Vif, APOBEC3G/APOBEC3F are found to
act against HIV-1. However, biological and biochemi-
cal basis for interaction of Vif and APOBEC3G/
APOBEC3F is not well understood yet.
APOBEC3G/APOBEC3F belong to a family of
polynucleotide cytidine deaminases with diverse
functions (1). Although it has been well estab-
lished that APOBEC3G/APOBEC3F are potent anti-
retroviral cellular factors, several other APOBEC
family members have been reported to be able to
inhibit HIV-1 (1). However, the extent of contribu-
tion by these APOBEC proteins to block or impede
HIV-1 replication remains to be determined.
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In this study, we have determined a single-cycle
viral infectivity of numerous HIV-1 vif mutants in
the presence of APOBEC3G or APOBEC3F, and
compared the results with growth characteristics of
the mutants in non-permissive H9 cells. In addition,
we have examined status of Vif/APOBEC3 com-
plexes in cells and virions by equilibrium density
centrifugation. We demonstrate here the distinct
interaction of Vif and the two APOBEC3 proteins.
MATERIALS AND METHODS
Cells
Human monolayer cell lines 293T (15) and MAGI
(16) were maintained in Eagles’s minimal essential
medium containing 10% heat-inactivated fetal bovine
serum.
Transfection
Sub-confluent 293T cells in 90 mm dishes were co-
transfected with a proviral clone and a flag-tagged
expression vector of APOBEC3G or APOBEC3F
(3, 4) by the calcium-phosphate co-precipitation
method (17). On day 2 post-transfection, cells and
cell-free virus samples were prepared as previously
described (3, 4, 17). Viral amount was determined
by the HIV-1 p24 antigen ELISA kit (ZeptoMetrix
Corp.).
MAGI assay
Viral single-cycle infectivity per 0.1 ng of Gag-p24
was determined by the MAGI assay as previously
described (16).
Analysis of Vif and APOBEC3G/APOBEC3F com-
plexes in cells and virions
Transfected 293T cells and virions produced in
the cells were lysed in a lysis buffer (1% Nonidet P-
40, 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM
EDTA and 1% protease inhibitor cocktail (Sigma-
Aldrich)). For preparation of virions, culture super-
natants from transfected 293T cells were filtered
through 0.45-μm filters, and partially purified by
ultracentrifugation through 25% sucrose for 2 h at
80,000g using SW41 rotor. Cell and virion lysates
were resolved by SDS-PAGE, and electrophoreti-
cally transferred to polyvinilidene fluolide mem-
branes. Membranes were treated with anti-FLAG
(Sigma-Aldrich), anti-Vif (NIH AIDS Research and
References Reagent Program) or anti-p24 (18) anti-
body, and visualized by ECL plus Western blotting
detection system (Amersham Pharmasia Biotech
Inc.). For analysis by equilibrium density centrifu-
gation, cell and virion lysates were loaded on the
top of 5-50% sucrose gradient, and spun for 16 h at
100,000g using SW41 rotor. Eight fractions were
collected from each tube, and precipitated by trichlo-
roacetic acid. Samples were then analyzed by im-
munoblotting as described above.
DNA constructs
Proviral vif mutant clones of HIV-1 NL4-3 have
been previously described (3, 4, 19).
RESULTS AND DISCUSSION
We have previously generated a series of HIV-1
vif mutants from wild-type (WT) NL4-3 clone, and
analyzed them biologically and biochemically (Fig.
1) (3, 4, 19). Approximately half of the site-directed
point mutants were defective for virus growth in
non-permissive H9 cells, and were predicted to be
susceptible to anti-viral activity of APOBEC3 pro-
teins. In fact, mutants designated W21A, S32A,
W38A, Y69A and H108A did not overcome the anti-
HIV-1 action of APOBEC3G/APOBEC3F (3, 4).
Moreover, while mutants Y40A and H43A did not
neutralize the activity of APOBEC3G, E76A and
W79A did not suppress APOBEC3F (3, 4).
In order to do a more systemic genetic analysis
of anti-APOBEC activity of HIV-1 Vif, we selected
fifteen clones from our proviral mutants (3, 4, 19)
as shown in Fig. 1. These included mutants carry-
ing mutations in known functional motifs or outside
the regions. A mutant without Vif (ΔVif) did not
grow at all in H9 cells (Fig. 1) (3, 19). The other
mutants except for H28A were growth-defective in
H9 cells to some extent (Fig. 1) (3, 19). The mu-
tants and expression vectors of APOBEC3G or
APOBEC3F were co-transfected into 293T cells,
and equal amounts of resultant viruses as deter-
mined by Gag-p24 ELISA were assayed for the
single-cycle infectivity in MAGI cells. All the mu-
tants were simultaneously examined for infectivity
in each experiment to know relative anti-APOBEC
activity. Fig. 2 shows the MAGI infectivity of various
viruses derived from proviral clones (Fig. 1). In
the presence of APOBEC3G and APOBEC3F, ΔVif
mutant displayed less than 20% and 30% infectivity
in a single-replication cycle, respectively, relative
to that of WT virus. As expected, L24A and H28A,
mutants with almost normal growth phenotype in
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H9 cells (Fig. 1) (3), behaved similarly with WT vi-
rus in the presence of APOBEC3G/APOBEC3F.
However, L24A was somewhat sensitive to A3F ac-
tivity in agreement with its slightly poor growth in
H9 cells (Fig. 1) (3). As can be easily seen in Fig. 2,
mutants other than L24A and H28A showed con-
siderable defects against APOBEC3G, APOBEC3F,
or both. Following mutants are typical examples :
Figure 2 : Single-cycle infectivity of various vif mutants in the presence of APOBEC3G/APOBEC3F. Virus samples were prepared
from 293T cells co-transfected with a proviral clone (15 μg) and an expression vector of flag tagged APOBEC3G/APOBEC3F (1 μg).
Single-cycle infectivity was determined by MAGI assay (16), and viral infectivity relative to that of WT NL4-3 clone is shown. A3G,
APOBEC3G ; A3F, APOBEC3F ; WT, wild- type virus NL4-3 ; ΔVif, Vif -minus virus NL-Nd (22).
Figure 1 : Major functional domains of HIV-1 Vif protein and its mutants used in this study. Functionally important domains or motifs
in Vif (2-4), and positions and designations of the mutants are indicated at the upper part. All mutants are derived from HIV-1 NL4-3
clone (17) (GenBank accession no. AF324493). At the lower part, growth property of mutant viruses in non-permissive H9 cells (3,
19) are summarized as follows. Wild type, virus growth similar to that of wild type virus ; No, no detectable virus growth ; Slightly
poor, virus growth kinetics are similar to those of wild type virus but virion production at the peak is around 50% of that by wild type
virus ; Poor, virus growth kinetics are significantly delayed relative to those of wild type virus (at least 3 days). Abbreviations : WT,
wild- type virus NL4-3 ; ΔVif, Vif -minus virus NL-Nd (22).
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Y40A/APOBEC3G, W79A/APOBEC3F, H108A/
APOBEC3G and APOBEC3F. The experiment was
repeated with similar results. In summary, Vif mu-
tants with a growth-defect in H9 cells were always
susceptible to anti-viral activity of APOBEC3G and/
or APOBEC3F to a various extent as shown in Table
1. Of note, viral ability to neutralize APOBEC3G/
APOBEC3F paralleled perfectly with viral growth
property in H9 cells (Fig. 1).
It has been reported that APOBEC3G/APOBEC3F
are present in high molecular mass (HMM) com-
plexes in some cells such as immortalized or acti-
vated primary T cells and that they reside in low
molecular mass (LMM) complexes in the resting
primary T cells (20, 21). It has also been shown
that only LMM complexes exhibit the cytidine
deaminase activity in vitro (20, 21). These findings
prompted us to examine whether HIV-1 Vif is asso-
ciated with the protein complexes of APOBEC3G/
APOBEC3F. We employed equilibrium density cen-
trifugation to segregate HIV-1 Vif and APOBEC3G/
APOBEC3F complexes. As a control Vif mutant,
H108A, which can bind to both of APOBEC3G/
APOBEC3F (3, 4) and are unable to neutralize
APOBEC3G/APOBEC3F (Table 1), was chosen
and used in this experiment. Cell and virion lysates
were prepared from 293T cells co-transfected with
an expression vector for APOBEC3G/APOBEC3F
and WT or H108A mutant proviral clone. Lysates
were then centrifuged onto 5-50% sucrose gradient,
and samples collected from centrifugal tubes were
subjected to immunoblot analysis. As shown in
Fig. 3, in the absence of Vif, while Gag-p24 was
mostly observed in low density fractions in virus-
producer cells and virions, APOBEC3G/APOBEC3F
were mainly present in high density fractions in
Table 1. Ability of various vif mutants to neutralize APOBEC3G/
APOBEC3F
Mutant A3G A3F
W21A - -
L24A ++ +
H28A ++ ++
S32A - -
W38A - -
Y40A - ++
H43A + ++
Y69A - -
E76A ++ -
W79A ++ -
D104A + +
H108A - -
C114S - -
C133S - -
H139A - -
A3G, APOBEC3G ; A3F, APOBEC3F.
++, Wild type ability ; +, Partially defective ; -, No ability.
Figure 3 : Profile of Vif and APOBEC3G/APOBEC3F complexes in producer cells and progeny virions as revealed by equilibrium
density centrifugation. Cell and virion lysates were prepared from 293T cells co-transfected with a proviral cloned and an expression
vector of APOBEC3G/APOBEC3F as described in the legend to Fig. 2, and were ultracentrifuged onto 5-50% sucrose gradient. Eight
fractions collected from each tube were then analyzed by immunoblotting. WT, wild- type virus NL4-3 ; ΔVif, Vif -minus virus NL-Nd
(22) ; Low, low density ; High, high density.
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the cells. In contrast, in virions, APOBEC3G and
APOBEC3F were found to predominantly exist in
LMM and HMM fractions, respectively. We also
examined APOBEC3G/APOBEC3F protein com-
plexes in the presence of WT and H108A Vif. WT
and H108A Vif did not affect the APOBEC3G/
APOBEC3F complexes in cells and virions signifi-
cantly (panels WT-Flag and H108A-Flag in Fig. 3).
However, in producer cells, the mutation of His108
partially shifted the Vif complexes from high to low
density (panels WT-Vif and H108A-Vif in Fig. 3).
Whether this small mutational effect is directly re-
lated to the inability of H108A-Vif to neutralize
APOBEC3G/APOBEC3F remains to be determined.
If related, the molecular basis for the phenotype
should be studied in detail. A systematic analysis of
the mutants other than H108A would give a more de-
finitive answer. In virions, WT and H108A Vif simi-
larly formed HMM protein complexes. In summary,
the results described above suggested that HIV-1
Vif interacts APOBEC3G/APOBEC3F in cells, and
that Vif may be contained in the APOBEC3F HMM
complex in virions.
In this study, we have demonstrated by using a va-
riety of HIV-1 vif mutant viruses that APOBEC3G/
APOBEC3F are essential to restrict viral replication
in target cells. All growth-defective mutants are
always sensitive to the strong anti-viral effect me-
diated by APOBEC3G and/or APOBEC3F (Fig. 1,
Fig. 2 and Table 1). This study has clearly indi-
cated that HIV-1 Vif interacts with APOBEC3G/
APOBEC3F differently. As illustrated in Fig. 1, there
are several motifs in HIV-1 Vif for binding to
APOBEC3G, APOBEC3F, or both. We confirmed
previous results and extended the observations re-
ported. Importantly, there may be another domain
around the site of W21-L24-S32-W38 for binding to
both APOBEC proteins (FG-box), not reported yet.
Our analysis of Vif-APOBEC protein complexes
here has also suggested that there may be molecu-
lar difference between interactions of Vif and the two
APOBEC proteins in virions. In virions, while Vif
and APOBEC3F was present in HMM fractions,
(particularly in the case of H108A Vif), APOBEC3G
resided in LMM fractions. In this regard, our find-
ing that H108A Vif does not bind to APOBEC3G in
virions but does in cells (4) is interesting. In con-
trast, WT Vif was shown to bind to APOBEC3G in
virions (4). More detailed biochemical studies would
reveal molecular structural basis for different in-
teraction of Vif and APOBEC3G/APOBEC3F.
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